News|Articles|August 23, 2022

COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of August 23, 2022

Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

US COVID-19 vaccination & booster dose status

US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of August 18, 2022, at 6:00 AM, EDT:

Fully vaccinated plus 2 booster doses:

• Aged ≥50 years 33.2%

• Aged ≥65 years 40.4%

Fully vaccinated plus 1 booster dose:

• Total US population 48.4%

Fully vaccinated in key age groups:

• Total US population 67.4%

• Aged ≥5 years 71.5%

• Aged ≥65 years 92%

US confirmed cases of COVID-19 and deaths

Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map, as of August 23, 2022 at 3:20 PM, EDT.

3 states with highest number of new cases in past 28 days

• California 365 730

• Texas 283 688

• Florida 227 895

• Total US confirmed cases 93 693 613

• Total US confirmed deaths 1 041 267

Global total COVID-19 confirmed cases, deaths, vaccine doses administered:

• Cases 597 316 092

• Deaths 6 456 961 • Vaccine doses administered 12 080 525 080

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of August 23, 2022

US COVID-19 vaccination & booster dose status

Fully vaccinated plus 2 booster doses:

• Aged ≥50 years 33.2%

• Aged ≥65 years 40.4%

Fully vaccinated plus 1 booster dose:

• Total US population 48.4%

Fully vaccinated in key age groups:

• Total US population 67.4%

• Aged ≥5 years 71.5%

• Aged ≥65 years 92%

US confirmed cases of COVID-19 and deaths

3 states with highest number of new cases in past 28 days

• California 365 730

• Texas 283 688

• Florida 227 895

• Total US confirmed cases 93 693 613

• Total US confirmed deaths 1 041 267

Global total COVID-19 confirmed cases, deaths, vaccine doses administered:

• Cases 597 316 092

• Deaths 6 456 961 • Vaccine doses administered 12 080 525 080

Newsletter

Related Content

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

Estetrol Phase 3 Trial Shows No Impact on Postmenopausal BP, Even in Women at High CV Risk

Caroline Mitchell, MD, Describes Toll of Genitourinary Syndrome of Menopause on QoL

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

Menopause: A Constellation of Syndromes Across 13 Body Systems

Latest CME

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Real Psychiatry 2026

2nd Annual Hawaii Cancer Conference

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

43rd Annual Miami Breast Cancer Conference®

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine

Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Raising Our Game in the Management of Hyperlipidemia: New Targets, New Tactics